R E S EARCH Open Access
Age of blood and recipient factors determine the
severity of transfusion-related acute lung injury
(TRALI)
John-Paul Tung1,2,3*, John F Fraser2,3,4, Maria Nataatmadja2,3, Kathryn I Colebourne3,4, Adrian G Barnett3,5,
Kristen M Glenister6
, Anna Y Zhou6
, Peter Wood2,7, Christopher C Silliman8,9,10 and Yoke L Fung1,2,3,11
Abstract
Introduction: Critical care patients frequently receive blood transfusions. Some reports show an association
between aged or stored blood and increased morbidity and mortality, including the development of transfusionï¿¾related acute lung injury (TRALI). However, the existence of conflicting data endorses the need for research to
either reject this association, or to confirm it and elucidate the underlying mechanisms.
Methods: Twenty-eight sheep were randomised into two groups, receiving saline or lipopolysaccharide (LPS).
Sheep were further randomised to also receive transfusion of pooled and heat-inactivated supernatant from fresh
(Day 1) or stored (Day 42) non-leucoreduced human packed red blood cells (PRBC) or an infusion of saline. TRALI
was defined by hypoxaemia during or within two hours of transfusion and histological evidence of pulmonary
oedema. Regression modelling compared physiology between groups, and to a previous study, using stored
platelet concentrates (PLT). Samples of the transfused blood products also underwent cytokine array and
biochemical analyses, and their neutrophil priming ability was measured in vitro.
Results: TRALI did not develop in sheep that first received saline-infusion. In contrast, 80% of sheep that first
received LPS-infusion developed TRALI following transfusion with â€œstored PRBC.â€ The decreased mean arterial
pressure and cardiac output as well as increased central venous pressure and body temperature were more severe
for TRALI induced by â€œstored PRBCâ€ than by â€œstored PLT.â€ Storage-related accumulation of several factors was
demonstrated in both â€œstored PRBCâ€ and â€œstored PLTâ€, and was associated with increased in vitro neutrophil
priming. Concentrations of several factors were higher in the â€œstored PRBCâ€ than in the â€œstored PLT,â€ however,
there was no difference to neutrophil priming in vitro.
Conclusions: In this in vivo ovine model, both recipient and blood product factors contributed to the
development of TRALI. Sick (LPS infused) sheep rather than healthy (saline infused) sheep predominantly
developed TRALI when transfused with supernatant from stored but not fresh PRBC. â€œStored PRBCâ€ induced a more
severe injury than â€œstored PLTâ€ and had a different storage lesion profile, suggesting that these outcomes may be
associated with storage lesion factors unique to each blood product type. Therefore, the transfusion of fresh rather
than stored PRBC may minimise the risk of TRALI.
* Correspondence: jtung@redcrossblood.org.au
1
Research and Development, Australian Red Cross Blood Service, 44 Musk
Avenue, Kelvin Grove, Brisbane, QLD 4059, Australia
Full list of author information is available at the end of the article
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Â© 2012 Tung et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.

Introduction
There is currently heightened concern about the negaï¿¾tive outcomes associated with transfusion of â€œolderâ€ or
stored blood products. Several studies have identified
the age of transfused packed red blood cell (PRBC)
units as an independent risk factor for increased morï¿¾bidity and mortality [1-4], including in the critical care
setting [5,6]. The existence of contradictory studies
[1,2,7,8], however, indicates that this is still a matter of
conjecture which necessitates further research.
Transfusion-related acute lung injury (TRALI) is a serï¿¾ious and potentially fatal adverse transfusion event that
has been associated with the transfusion of stored blood
products [9-12]. Similar to acute lung injury (ALI) and
acute respiratory distress syndrome (ARDS), TRALI
manifests as respiratory distress with symptoms of
hypoxaemia and pulmonary oedema [13-16]. However,
in the case of TRALI, the onset of symptoms is tempoï¿¾rally associated with transfusion (developing either durï¿¾ing or within six hours of transfusion) [13-16]. TRALI
has been reported by haemovigilance programs to be
the most frequent cause of transfusion-related mortality
in the US [17] and a leading cause of transfusion-related
morbidity and mortality elsewhere [18,19]. However,
TRALI is thought to be under-diagnosed and underï¿¾reported, particularly in the busy critical care setting
where the development of symptoms may be attributed
to multiple other disease processes or therapeutic interï¿¾ventions (for example, post cardiopulmonary bypass)
rather than transfusion [20-22]. Indeed, a prospective
study, which was not limited by the under-diagnosis and
under-reporting inherent to haemo-vigilance programs,
described the incidence of TRALI in the critical care
setting as 8% [23], while a retrospective study described
an incidence of 5% [24]. Interestingly, another prospecï¿¾tive study reported an incidence of TRALI of 29% in
end-stage liver disease (ESLD) patients admitted to critiï¿¾cal care with gastrointestinal (GI) bleeding, suggesting
that particular patient groups within the critical care
setting may be at further risk of TRALI [25]. The norï¿¾mal rate of mortality in cases of TRALI is estimated to
be 5 to 10% [16]; however, it may be higher in critical
care patients as a mortality rate of 41% has been
reported, although this was not adjusted for the influï¿¾ence of other morbidities [23].
TRALI is postulated to develop as the result of two
separate clinical events [15,16]. The first or priming
event is due to the patientâ€™s primary disease or condiï¿¾tion which results in activation of the pulmonary
endothelium and the accumulation of primed, adherent
neutrophils in the lung [15,16]. The second event is the
subsequent blood transfusion, whereby the primed neuï¿¾trophils are activated by either a leucocyte antibody or
biological response modifiers (BRM) present in the
transfused blood product [15,16]. Activation of the
primed neutrophils results in augmented release of their
microbicidal arsenal, which causes collateral injury to
the pulmonary endothelium that manifests as capillary
leak, and clinically as TRALI [15,16]. Thus the twoï¿¾event mechanism proposes that both recipient and
blood product factors contribute to TRALI pathogenesis.
Critical care patients may, therefore, be particularly susï¿¾ceptible to the development of TRALI, first, because of
the severity of their underlying illness, and second,
because they are more likely to receive blood transfusion
[14,15,23,25].
Current risk reduction strategies (the preferential use
of plasma from male donors, or the screening of donors
for leucocyte antibodies) address the risk of TRALI
associated with transfusion of leucocyte antibodies
rather than BRM [17,26,27]. These BRM are thought to
accumulate as part of the storage lesion of cellular
blood products, such as packed red blood cell (PRBC)
and platelet concentrates (PLT) [28-31]. Data from in
vivo animal models as well as retrospective and in vitro
studies indicate that stored PRBC or PLT may pose a
greater risk of inducing TRALI than equivalent fresh
PRBC or PLT [9-12]. The role of blood product factors,
therefore, requires further elucidation. Using an estabï¿¾lished in vivo ovine model, this study investigated the
hypotheses that: (i) both recipient factors (lipopolysacï¿¾charide (LPS) infusion to approximate clinical infection)
and blood product factors (stored PRBC) would be
required to induce TRALI, and (ii) that differences in
the storage lesions of PRBC and PLT would result in
differences in the haemodynamic and respiratory
changes associated with the development of TRALI.
Materials and methods
All experiments were approved by the University Aniï¿¾mal Ethics Committee of the Queensland University of
Technology, the Health Sciences Animal Ethics Comï¿¾mittee of the University of Queensland and the Ethics
Committee of the Australian Red Cross Blood Service,
and conducted in accordance with the Australian Code
of Practice for the Care and Use of Animals for Scientiï¿¾fic Purposes.
Collection and preparation of supernatant pools for
transfusion
Seventy units of non-leucoreduced PRBC units were
prepared by the Australian Red Cross Blood Service
using standard procedures, including collection into
citrate phosphate dextrose (CPD) and the addition of
saline-adenine-glucose-mannitol (SAGM) additive soluï¿¾tion. Thirty-five PRBC units were processed on Day 1 to
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 2 of 14

obtain a â€œfresh PRBCâ€ supernatant pool. The remaining
35 PRBC units were stored under standard conditions
(4Â°C) until expiry (Day 42), when they were processed
to obtain a â€œstored PRBCâ€ supernatant pool. Supernaï¿¾tant pools were prepared by centrifugation as previously
described [10] and were similarly heat-inactivated (56Â°C
for 30 minutes) to eradicate the non-specific actions of
complement and fibrinogen [12]. Similar pools of heatï¿¾inactivated Day 1 and Day 5 whole blood PLT supernaï¿¾tant were prepared in a previous study (d1-PLT-S/N or
â€œfresh PLTâ€ and d5-PLT-S/N or â€œstored PLTâ€) [10], and
aliquots were stored for further analyses in the present
study.
Transfusion protocol
The in vivo transfusion protocol has been previously
described in detail [10]. Management of anaesthesia,
mechanical ventilation, supplemental oxygen, voluemia
and infusion/transfusion protocols were identical to the
previous study [10]. Briefly, 28 female sheep (Ovis aries)
received intravenous buprenorphine analgesia and ketaï¿¾mine/midazolam anaesthesia supplemented with butorï¿¾phanol where required, and were mechanically ventilated
and instrumented [10]. A one-hour period of stabilisation
was allowed, after which hemodynamic monitoring and
baseline bloods were collected. Sheep were randomly
assigned into six groups to receive either saline or LPS as
a first event, and then either saline or â€œfresh PRBCâ€ or
â€œstored PRBCâ€ as a second event (Table 1). Either 30 ml
of saline or LPS from Escherichia coli serotype O55:B5
(15 Î¼g/kg based upon previous titration studies [10];
Sigma-Aldrich, Castle Hill, NSW, Australia) were infused
intravenously into the sheep over 30 minutes (first
event), followed by monitoring for 1 hour. For the second
event, either saline or â€œfresh PRBCâ€ or â€œstored PRBCâ€
(10% of total blood volume) were infused into the sheep
(200 ml/hr). Since the majority of clinical cases of TRALI
develop within this time-frame [16], sheep were then
monitored for two hours, after which they were euthaï¿¾nised with 12 ml pentobarbitone sodium (325 mg/ml;
Virbac Animal Health, Milpera, NSW, Australia).
Sample collection
Samples of venous blood were collected at baseline, post
first event infusion, post second event infusion, and preï¿¾mortem. Samples of arterial blood for arterial blood gas
(ABG) measurements were collected at 30-minute interï¿¾vals throughout the experiment.
Post-mortem tissue samples were collected from the
lower lobe of the left lung, for both histological and wet/
dry weight analyses. Samples for histology were immediï¿¾ately fixed in 10% formalin and then processed and
embedded in paraffin using routine methods. Histological
examination of lung sections was as previously described
[10]. In brief, 4 Î¼m sections of lung underwent haemotoxyï¿¾lin and eosin staining before being semi-quantitatively
assessed for pulmonary oedema by two researchers blinded
to the experimental groupings. Twenty fields of lung histolï¿¾ogy for each section were photographed and graded for
pulmonary oedema via a scoring system of 0- normal, 1-
mild oedema, 2- moderate oedema and 3- severe oedema.
Samples for wet/dry weight analysis were immediately
weighed (wet weight) and then dried in an oven at 50Â°C
until a stable weight was achieved (dry weight).
Assessment of TRALI and ALI
TRALI was assessed as previously described by both the
development of hypoxaemia during or within two hours
Table 1 Groups of sheep and incidence of TRALI
Group names 1st event 2nd event n Hypoxaemia Pulmonary oedema ALI/TRALI
Number positive (% positive)
Sham Saline Saline 5 0 0 0 (0%)
Saline-fresh Saline â€œFresh PRBCâ€ 40 0 0 (0%)
Saline-stored Saline â€œStored PRBCâ€ 31 0 0 (0%)
LPS-control LPS Saline 6 0 2 0 (0%)
LPS-fresh LPS â€œFresh PRBCâ€ 51 1 1 (20%)
LPS-stored LPS â€œStored PRBCâ€ 55 4 4 (80%)a
Previous study [10] LPS â€œFresh PLTâ€ (d1-PLT-S/N) 5 2 3 1 (20%)
Previous study [10] LPS â€œStored PLTâ€ (d5-PLT-S/N) 5 4 5 4 (80%)
ALI, acute lung injury; d1-PLT-S/N, pooled heat-inactivated supernatant from Day 1 human platelet concentrates; d5-PLT-S/N, pooled heat-inactivated supernatant
from Day 5 human platelet concentrates; â€œfresh PLTâ€, pooled heat-inactivated supernatant from Day 1 human platelet concentrates; â€œfresh PRBC,â€ pooled heatï¿¾inactivated supernatant from Day 1 human PRBC; LPS, lipopolysaccharide; n, number of sheep in group; â€œstored PLTâ€, pooled heat-inactivated supernatant from
Day 5 human platelet concentrates; â€œstored PRBC,â€ pooled heat-inactivated supernatant from day 42 human packed red blood cell concentrates; TRALI,
transfusion-related acute lung injury. Sheep were randomly assigned into the groups described above. Sheep were infused with either saline or LPS as a first
event. Sheep were subsequently infused with saline, or transfused with either â€œfresh PRBCâ€ or â€œstored PRBCâ€ as a second event. TRALI was defined by the
development of both hypoxaemia either during or within two hours of the second event transfusion, and pulmonary oedema upon blinded histological
assessment of post- mortem lung sections. a LPS infusion as a first event followed by the subsequent transfusion of stored PRBC as the second event
predisposed the sheep towards the development of TRALI (by Fisherâ€™s exact test: P = 0.01 LPS-stored vs. saline-fresh, saline-stored and LPS-fresh without post hoc
exclusion, or P = 0.048 LPS-stored vs. LPS-fresh and P = 0.003 LPS-stored vs. saline-fresh, saline-stored and LPS-fresh with post hoc exclusion).
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 3 of 14

of transfusion (second event) and histological evidence
of pulmonary oedema (average score > 1) [10]. Hypoxï¿¾aemia was defined as PaO2/FiO2 < 300 on at least two
consecutive blood gas samples either during or following
infusion of the second event. Where PaO2/FiO2 was
below 300 prior to transfusion, a positive result for
hypoxaemia was assessed by a worsening of PaO2/FiO2
for at least two consecutive blood gas samples either
during or following transfusion. Sheep infused with salï¿¾ine as a control for transfusion were assessed for acute
lung injury (ALI) rather than TRALI.
Measurements and assays used
Physiological measurements were recorded continuously
throughout the experiments as described previously
[10]. Blood-gas analyses were performed on an autoï¿¾mated blood gas analyser (ABL System 625, Radiometer,
Copenhagen, Denmark).
Cytokine concentrations in the â€œfresh PRBCâ€ and
â€œstored PRBCâ€ prepared in this study as well as the
â€œfresh PLTâ€ and â€œstored PLTâ€ prepared previously [10],
were semi-quantitatively characterised with a commerï¿¾cial microarray pre-loaded with 79 cytokines including
epidermal growth factor (EGF), epithelial derived neuï¿¾trophil activating 78 (ENA-78), growth related oncogene
alpha (GRO), insulin-like growth factor-binding protein
1 (IGFBP-1), insulin-like growth factor (IGF), interleukin
8 (IL-8), interleukin 16 (IL-16), homologous to lymphoï¿¾toxins, inducible expression, competes with HSV glycoï¿¾protein D for HVEM, a receptor expressed on Tï¿¾lymphocytes (LIGHT), monocyte chemotactic protein 1
(MCP-1), macrophage inhibitory factor (MIF) and plateï¿¾let-derived growth factor BB (PDGF-BB) (Human Cytoï¿¾kine Array V, RayBiotech, Atlanta, GA, USA). Analysis
of the relative light intensity (RLI) of the corresponding
spots via PDQuest Basic 2-D Gel Analysis Software
(BioRad, Hercules, CA, USA) provided a relative meaï¿¾surement of the concentration of each specific cytokine
or chemokine. Proteins that appeared to increase with
storage were then quantified by commercial ELISA kits
for EGF, ENA-78, GRO-a, IL-8, IL-16, and MCP-1
(R&D Systems, Minneapolis, MN, USA), and also for
soluble CD40 ligand (sCD40L) (Bender MedSystems,
Vienna, Austria) according to the manufacturersâ€™
instructions. Where concentrations were above the
detection range of the kit, samples were diluted accordï¿¾ing to the manufacturersâ€™ instructions to obtain a value
within the detectable range, which was then multiplied
by the dilution factor to obtain the final concentration.
Using methods previously described [30-32], the abilï¿¾ity of the PLT and PRBC supernatants to prime N-forï¿¾mylmethionyl-leucyl-phenylalanine (fMLP) induced
respiratory burst function of human neutrophils was
measured in vitro and compared to that of buffer, fresh
autologous plasma and platelet-activating factor (PAF).
Statistical analyses
The clinical incidence of TRALI was compared using
two-way contingency tables and the Fisherâ€™s exact test.
Physiological differences between groups were made
using a two-way ANOVA with Bonferroniâ€™s multiple
comparisons adjustment. Physiological data were subseï¿¾quently modelled using a mixed model with a random
intercept for each sheep in the R statistical package [33].
These models were used to examine differences between
groups over time whilst accounting for repeated data
[34]. Data from LPS-treated sheep that developed
TRALI due to either â€œstored PRBCâ€ or â€œstored PLTâ€
transfusion were also compared using mixed modelling.
Neutrophil priming ability of the different supernatants
and controls was compared using a one-way ANOVA
with Bonferroniâ€™s multiple comparisons adjustment. In
all cases statistical significance was determined at P <
0.05.
Results
TRALI did not develop in healthy sheep
The absence of ALI in the sham group demonstrated
that the anaesthetic, surgical and experimental protocols
did not induce lung injury (Table 1). Similarly, sheep
that were infused with saline as a control first event and
then transfused with either â€œfresh PRBCâ€ or â€œstored
PRBC,â€ (that is, saline-fresh and saline-stored groups)
did not develop TRALI. A single sheep displayed eviï¿¾dence of hypoxaemia that worsened following transfuï¿¾sion of â€œstored PRBC.â€
Transfusion of â€œstored PRBCâ€ caused TRALI in LPS-primed
sheep
The dose of LPS, infused as a first event resulted in proï¿¾found neutropenia (mean Â± SD: 2.03 Â± 0.86 neutrophils
Ã— 109
/L at baseline vs. 0.14 Â± 0.03 neutrophils Ã— 109
/L
post-LPS; P < 0.0001 by paired t-test). The LPS-control
group of sheep confirmed that this dose of LPS was
insufficient to induce ALI (Table 1). One of the five
LPS-fresh sheep and four of the five sheep in the LPSï¿¾stored group were diagnosed with TRALI (Table 1).
This demonstrated that TRALI predominantly develï¿¾oped in sheep that received LPS-infusion followed by
â€œstored PRBCâ€ transfusion (P = 0.01 LPS-stored group
vs. saline-fresh, saline-stored and LPS-fresh groups).
Analysis of the lung section wet/dry weights (mean Â±
SD: sham = 5.33 Â± 0.21; saline-fresh = 5.53 Â± 0.37; salï¿¾ine-stored = 5.89 Â± 0.52; LPS-control = 5.84 Â± 0.96;
LPS-fresh = 5.38 Â± 0.73; LPS-stored = 6.99 Â± 1.2) conï¿¾firmed this finding (P = 0.0038 LPS-stored group vs.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 4 of 14

saline-fresh, saline-stored and LPS-fresh groups by
unpaired t-test). There was evidence of widespread neuï¿¾trophil infiltration in the lungs of LPS-stored sheep (Figï¿¾ure 1F) compared to those of sham sheep (Figure 1E).
Of the six sheep that were diagnosed with hypoxaemia,
five diagnoses (one in the LPS-fresh group and four in
the LPS-stored group) were based upon a sustained
worsening of hypoxaemia that was evident prior to
transfusion of â€œstored PRBC.â€
Haemodynamic and respiratory changes associated with
the development of TRALI
Sheep in the LPS-stored group displayed changes to
haemodynamic and respiratory changes relative to both
sham and LPS-control groupsâ€™ lower mean arterial presï¿¾sure (MAP), cardiac output (CO), PaO2, and oxygen
saturation (O2 sat) as well as higher pulmonary artery
pressure (PAP) relative to sham (Figure 2; P < 0.05 for
all comparisons). These sheep also displayed lower static
pulmonary compliance (Cstat), CO, PaO2 and O2sat
(oxygen saturation) as well as higher PAP relative to
LPS-control (P < 0.05 for all comparisons). There were
also differences between the saline-stored and sham
groups, demonstrated in an increased PAP relative to
sham (Figure 2; P < 0.05), and while there was also a
trend towards decreased PaO2, the increased PAP was
the only significant change observed in the saline-stored
and LPS-fresh groups.
To account for differences both in individual sheep
and in groups of sheep, mixed modelling was used to
further characterise the haemodynamic and respiratory
changes associated with the development of TRALI
(Table 2). Sheep in the LPS-stored group displayed
changes relative to sham, LPS-control and LPS-fresh
groups (Table 2; by mixed models: P < 0.001 for all
comparisons).
â€œStored PRBCâ€ caused more severe injury than â€œstored
PLTâ€
To investigate whether TRALI induced by â€œstored
PRBCâ€ was more severe than that induced by â€œstored
PLTâ€ in a previous study [10], data from the four sheep
that developed TRALI in each of these two groups were
used to create new mixed models (Table 3). These anaï¿¾lyses indicated that TRALI induced by â€œstored PRBCâ€
resulted in lower MAP (P < 0.0001) and CO (P =
0.0145), as well as higher CVP (P < 0.0001) and body
temperature (P < 0.0001) relative to that induced by
â€œstored PLTâ€. There were also trends towards lower
PaO2 and increased PAP, although these did not reach
significance in this study. These changes indicate that
TRALI induced by â€œstored PRBCâ€ results in more severe
haemodynamic changes than that induced by â€œstored
PLTâ€.
Differences in the composition of these products may
explain the differing injury observed
We hypothesised that the observed haemodynamic difï¿¾ferences may be related to differences in the composiï¿¾tion of the different blood products. Biochemical
changes related to storage in the â€œstored PRBCâ€ and
â€œstored PLTâ€ were normal for stored blood products
(Table 4).
Soluble CD40L levels were measured because this
molecule has been associated with TRALI pathogenesis
[29,35]. Storage resulted in accumulation of sCD40L in
both â€œstored PRBCâ€ and in â€œstored PLT,â€ with the forï¿¾mer having higher levels (Table 4). However, these levels
were much lower than those previously reported in
units of Day 42 PRBC or Day 5 PLT [29,35]. To investiï¿¾gate whether heat-inactivation may also have reduced
levels of sCD40L, we measured levels in equivalent nonï¿¾heat-inactivated supernatant pools: PLT (Day 1: 1.85 ng/
ml vs. Day 5: 9.25 ng/ml) and PRBC (Day 1: 0.40 ng/ml
vs. Day 42: 8.36 ng/ml). This confirmed that heat-inactiï¿¾vation was responsible for the reduced levels of sCD40L
evident in both â€œstored PRBCâ€ and â€œstored PLT.â€
In contrast to sCD40L, no significant differences
resulting from heat-inactivation were found in the conï¿¾centrations of EGF, ENA-78, GRO-a, IL-8, IL-16 and
MCP-1 (data not shown). As shown in Table 4 the conï¿¾centrations of the EGF, ENA-78 and GRO-a, were
increased in both the â€œstored PRBCâ€ and the â€œstored
PLTâ€ compared to the respective fresh product ("fresh
PRBCâ€ and â€œfresh PLTâ€). However, concentrations of ILï¿¾8, IL-16 and MCP-1 were only increased in â€œstored
PRBCâ€ (Table 4). Hence, there were more storageï¿¾related changes in cytokine concentration in â€œstored
PRBCâ€ than in â€œstored PLT.â€ Comparison of the two
stored products also revealed that â€œstored PRBCâ€ conï¿¾tained higher concentrations of EGF, IL-8, IL-16 and
MCP-1, while â€œstored PLTâ€ contained higher concentraï¿¾tions of ENA-78 (Table 4). Together these results
demonstrate that there were storage-related changes,
which were different depending on the blood product
type (that is, â€œstored PRBCâ€ vs. â€œstored PLTâ€).
Differing composition did not result in differences in
neutrophil priming
Because the neutrophil respiratory burst function plays a
key role in the pathogenesis of TRALI [36], we comï¿¾pared the ability of â€œstored PRBCâ€ and â€œstored PLTâ€ to
prime fMLP-induced activation of the respiratory burst
in human neutrophils in vitro. In accordance with preï¿¾vious studies [31,37], â€œstored PRBCâ€ and â€œstored PLTâ€
both demonstrated greater priming ability than equivaï¿¾lent fresh supernatants (P < 0.001 in both cases; Figure
3). However, no difference was observed between the
â€œstored PRBCâ€ and the â€œstored PLTâ€ (Figure 3).
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 5 of 14

Figure 1 Representative histology. Representative haemotoxylin and eosin stained lung sections analysed histologically for pulmonary
oedema. These range from no pulmonary oedema (A) through to mild (B), moderate (C) and severe (D) pulmonary oedema. Neutrophils were
identified by morphological assessment and are indicated by the blue arrows (E and F). In contrast to sham sheep (E), there was widespread
evidence of neutrophil infiltration in the lungs of LPS-stored sheep (F). LPS, lipopolysaccharide.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 6 of 14

  
  



 
 
  
  
 	  
  	  
 
 	





  

 ! 
	
























	





	



 
 ! 




	

	

	

 
Figure 2 Haemodynamic and respiratory changes. Averaged data over 30-minute periods for each of the six groups of sheep. The first event
(either saline or LPS) was infused from 0 to 30 minutes and the second event (either saline, â€œfresh PRBCâ€ or â€œstored PRBCâ€) was infused from 90
to 150 minutes. The left column represents sheep receiving saline-infusion as a first event (that is, sham, saline-fresh and saline-stored groups),
and the right column represents sheep receiving LPS-infusion as a first event (that is, LPS-control, LPS-fresh and LPS-stored groups). Dashed lines
at O2sat = 90% and PaO2 = 125 mmHg (FiO2 was 40%, therefore PaO2/FiO2 = 300) represent clinical cut-offs for hypoxaemia. LPS-stored sheep
developed lower MAP, CO, PaO2, and O2 sat as well as higher PAP relative to sham sheep. Also, saline-stored sheep displayed increased PAP
relative to sham sheep. # P < 0.05 vs. sham group using a two-way ANOVA with Bonferroniâ€™s multiple comparisons adjustment. LPS-stored sheep
developed lower static pulmonary compliance, CO, PaO2, and O2 sat as well as higher PAP relative to the LPS-control group. * P < 0.05 vs. LPSï¿¾control using a two-way ANOVA with Bonferroniâ€™s multiple comparisons adjustment. ANOVA, analysis of variance; CO, continuous cardiac output;
FiO2, fraction of inspired oxygen; â€œfresh PRBC,â€ pooled heat-inactivated supernatant from Day 1 human PRBC; LPS, lipopolysaccharide; MAP, mean
arterial pressure; O2sat, oxygen saturation; PaO2, arterial partial pressure of oxygen; PAP, pulmonary artery pressure; â€œstored PRBC,â€ pooled heatï¿¾inactivated supernatant from Day 42 human PRBC; TRALI, transfusion-related acute lung injury.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 7 of 14

Discussion
The development of respiratory dysfunction comproï¿¾mises the recovery of severely ill patients and may conï¿¾tribute to their morbidity and death. While some
patients may progress to either ALI or ARDS, the assoï¿¾ciation with recent blood transfusion may be overlooked
[20-22]. Thus, many cases of ALI/ARDS may in fact
represent TRALI, and the true scale of the risks posed
by TRALI in the critical care setting are likely to be
under-appreciated. Prospective studies have revealed an
incidence of TRALI ranging from 5 to 8% in general criï¿¾tical care patients [23,24] and up to 29% in ELSD critiï¿¾cal care patients admitted with GI bleeding [25]. This
study provides additional evidence that both patient and
blood product factors contribute to the development of
TRALI, and that the type of blood product influences
the severity of injury.
Patients with severe illness are hypothesised to be
more likely to develop TRALI, thus critically ill patients
may be particularly susceptible to the development of
TRALI [14,22]. In this study, TRALI only developed in
â€œillâ€ sheep and did not develop in any of the â€œhealthyâ€
sheep, even following transfusion of â€œstored PRBC.â€ This
is consistent with previous TRALI models, in which
both a clinical first event, either LPS-infusion or, in the
case of mice, their exposure to a germ environment, and
an appropriate second event (that is, stored blood or
leucocyte antibody) were required for TRALI to develop
[9,10,12,38,39]. Thus, this study reaffirms the imporï¿¾tance of patient factors in the development of TRALI.
Table 2 Haemodynamic changes
Sham Saline-fresh Saline-stored LPS-control LPS-fresh LPS-stored
(n = 5) (n = 4) (n = 3) (n = 6) (n = 5) (n = 5)
PAP (mmHg) 14.7 Â± 0.7 18.4 Â± 0.7 24.7 Â± 0.7 27.0 Â± 0.6 30.7 Â± 0.7 37.0 Â± 0.7a, b, c
(10 to 19) (4 to 28) (9 to 60) (5 to 47) (6 to 62) (13 to 89)
MAP (mmHg) 108.3 Â± 2.2 107.3 Â± 2.3 110.6 Â± 2.3 90.0 Â± 2.0 89.0 Â± 2.3 98.1 Â± 2.3a, c
(67 to 146) (64 to 172) (55 to 155) (37 to 130) (44 to 169) (30 to 149)
CVP (mmHg) 6.0 Â± 0.6 5.1 Â± 0.6 5.5 Â± 0.6 5.7 Â± 0.6 4.8 Â± 0.6 5.2 Â± 0.6a
(1 to 20) (0 to 13) (0 to 20) (0 to 17) (0 to 18) (1 to 18)
Heart rate (bpm) 102.5 Â± 2.9 112.9 Â± 3.0 113.7 Â± 3.0 111.4 Â± 2.7 121.8 Â± 3.0 122.6 Â± 3.0a
(65 to 147) (60 to 132) (70 to 192) (52 to 210) (57 to 182) (65 to 166)
O2sat (%) 97.2 Â± 0.6 97.7 Â± 0.7 96.8 Â± 0.7 94.9 Â± 0.6 95.4 Â± 0.7 94.5 Â± 0.7a
(81 to 100) (80 to 100) (86 to 100) (69 to 100) (73 to 100) (71 to 100)
EtCO2 (mmHg) 32.9 Â± 1.2 32.5 Â± 1.2 30.6 Â± 1.2 34.0 Â± 1.2 33.6 Â± 1.2 31.7 Â± 1.2
(20 to 47) (23 to 39) (10 to 44) (13 to 54) (17 to 52) (15 to 55)
CO (L/min) 4.6 Â± 0.2 4.6 Â± 0.2 3.7 Â± 0.2 4.5 Â± 0.2 4.5 Â± 0.2 3.6 Â± 0.2a, b, c
(3.1 to 6.6) (3.5 to 6.0) (1.8 to 7.2) (1.1 to 7.1) (1.1 to 5.8) (1.4 to 5.0)
SvO2 (%) 70.2 Â± 1.5 73.3 Â± 1.5 65.9 Â± 1.5 72.5 Â± 1.4 75.6 Â± 1.5 68.3 Â± 1.5a
(44 to 82) (33 to 81) (38 to 84) (48 to 91) (48 to 86) (22 to 77)
Body temperature (Â°C) 38.7 Â± 0.1 38.5 Â± 0.1 38.7 Â± 0.1 38.7 Â± 0.1 38.5 Â± 0.1 38.7 Â± 0.1
(38.1 to 39.8) (37.2 to 40.2) (38.0 to 39.4) (38.0 to 41.4) (37.1 to 41.5) (37.7 to 41.1)
PaO2 (mmHg) 184.8 Â± 11.9 193.2 Â± 13.0 152.6 Â± 13.1 131.1 Â± 7.4 139.5 Â± 13.2 98.9 Â± 13.2a, b, c
(122 to 216) (76.5 to 210) (72.2 to 205) (94.8 to 215) (64.8 to 233) (50.0 to 210)
PaCO2 (mmHg) 37.7 Â± 2.0 37.0 Â± 2.2 39.3 Â± 2.2 39.8 Â± 1.4 39.1 Â± 2.1 41.4 Â± 2.2a
(30.5 to 42.3) (24.9 to 40.6) (22.7 to 51.5) (28.5 to 54.5) (23.7 to 51.9) (27.7 to 70.6)
Cstat (L/kPa) 38.4 Â± 3.7 35.1 Â± 4.0 30.4 Â± 4.0 27.4 Â± 2.5 24.1 Â± 4.0 19.4 Â± 4.0a, b, c
(26.3 to 63.6) (22.3 to 39.0) (15.9 to 43.6) (14.2 to 73.3) (12.0 to 65.0) (9.3 to 66.7)
PaO2/FiO2 (FiO2 = 40%) 462.0 Â± 11.9 483.0 Â± 13.0 381.5 Â± 13.1 327.8 Â± 7.4 348.8 Â± 13.2 247.3 Â± 13.2a, b, c
(305 to 540) (191 to 525) (181 to 513) (237 to 537) (162 to 583) (125 to 525)
CO, cardiac output; Cstat, static pulmonary compliance; CVP, central venous pressure; EtCO2, end tidal carbon dioxide; FiO2, fraction of inspired oxygen; â€œfresh
PRBCâ€, pooled heat-inactivated supernatant from day 1 human packed red blood cell concentrates; LPS, lipopolysaccharide; LPS-control, group of sheep that
received LPS followed by saline; LPS-fresh, group of sheep that received LPS followed by â€œfresh PRBC"; LPS-stored, group of sheep that received LPS followed by
â€œstored PRBC"; MAP, mean arterial pressure; O2sat, oxygen saturation; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial partial pressure of oxygen;
saline-fresh, group of sheep that received saline followed by â€œfresh PRBC"; saline-stored, group of sheep that received saline followed by â€œstored PRBC"; PAP,
pulmonary artery pressure; SEM, standard error of the mean; sham, group of sheep that received saline followed by saline; â€œstored PRBCâ€, pooled heat-inactivated
supernatant from day 42 human packed red blood cell concentrates; SvO2, mixed venous oxygen saturation; TRALI, transfusion-related acute lung injury.
Averages Â± SEM (minimum-maximum) for each group are shown. Averages and SEM were calculated using mixed models. Minimum and maximum values were
from recorded data. a P < 0.05 vs. sham. b P < 0.05 vs. LPS -control. c P < 0.05 vs. LPS-fresh.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 8 of 14

The age of the transfused blood product was also
found to be crucial to the development of TRALI, as it
predominantly developed in LPS-primed sheep transï¿¾fused with â€œstored PRBCâ€ and not â€œfresh PRBC.â€ This
adds to findings from previous in vivo models in which
TRALI has been described subsequent to transfusion
with supernatant from stored human PRBC in rats [12]
or stored human PLT in both rats [40] and in sheep
[10]. During routine storage of PRBC and PLT, proteins
and lipids (or their metabolites) are released by cells
into the storage medium [28-31,41,42]. These soluble
factors are retained in the supernatant and are thought
to contribute to the development of TRALI
[1-3,5,6,11,12,28-31,43-45], although some studies have
also implicated the transfused cells [44,46]. In this study,
cytokine array and ELISA analyses were used to identify
the soluble factors that may have contributed to the
development of TRALI in the sheep. It was demonï¿¾strated that â€œstored PRBCâ€ contained higher levels of
EGF, ENA-78, GRO-a, IL-8, IL-16 and MCP-1 relative
to â€œfresh PRBCâ€, while levels of lactate and potassium
increased and levels of sodium decreased. Since neutroï¿¾phils are key effector cells in TRALI pathogenesis, the
biological relevance of these changes was confirmed by
the increased in vitro neutrophil priming ability present
in â€œstored PRBCâ€ compared to â€œfresh PRBCâ€.
Heat-inactivation of the human blood product superï¿¾natant used in this and in previous studies
[9,10,12,28,39] was necessary to prevent widespread
thrombus formation and mortality due to non-specific
actions of complement and fibrinogen [9,12,39]; howï¿¾ever, represents a limitation of these models. As was
demonstrated for sCD40L, heat-inactivation may reduce
the concentration of some protein BRMs; however,
levels of EGF, ENA-78, GRO-a, IL-8, IL-16 and MCP-1
were all unaffected by heat-inactivation. It remains posï¿¾sible that heat-inactivation may have affected other
parameters not investigated, and may have influenced
the development of TRALI. The alternative approach of
transfusing homologous ovine with PRBC rather than
with heat-inactivated supernatant from human PRBC
was not used in this study because of the limitations of
Table 3 Comparison of haemodynamic changes in TRALI
induced by either â€œstored PLTâ€ or â€œstored PRBCâ€
â€œstored PLTâ€ (n =
4)
â€œstored PRBCâ€ (n =
4)
P
PAP (mmHg) 24.4 Â± 2.1 28.7 Â± 2.4 0.0946
MAP (mmHg) 87.9 Â± 5.5 74.5 Â± 5.6 <
0.0001
CVP (mmHg) 3.0 Â± 1.2 7.8 Â± 1.2 <
0.0001
Heart rate
(bpm)
112.7 Â± 4.7 117.3 Â± 5.4 0.5262
O2sat (%) 92.6 Â± 2.8 89.5 Â± 3.1 0.3598
EtCO2 (mmHg) 38.8 Â± 3.0 33.3 Â± 5.6 0.2253
CO (L/min) 4.9 Â± 0.3 3.7 Â± 0.4 < 0.05
SvO2 (%) 70.6 Â± 5.9 62.3 Â± 6.8 0.3499
Body temp (Â°C) 39.1. Â± 0.3 40.3 Â± 0.3 <
0.0001
PaO2 (mmHg) 103.9 Â± 14.3 68.5 Â± 16.4 0.1086
PaCO2 (mmHg) 42.7 Â± 3.3 41.0 Â± 3.7 0.7228
Cstat (L/kPa) 17.5 Â± 3.0 15.7 Â± 2.4 0.6305
PaO2/FiO2 259.8 Â± 14.3 171.3 Â± 16.4 0.1086
CO, cardiac output; Cstat, static pulmonary compliance; CVP, central venous
pressure; EtCO2, end tidal carbon dioxide; n, number of sheep in group; FiO2,
fraction of inspired oxygen (= 40%); LPS, lipopolysaccharide; MAP, mean
arterial pressure; O2sat, oxygen saturation; PaCO2, arterial partial pressure of
carbon dioxide; PaO2, arterial partial pressure of oxygen; PAP, pulmonary
artery pressure; â€œstored PLTâ€, pooled heat-inactivated supernatant from Day 5
non-leucoreduced human platelet concentrates; â€œstored PRBCâ€, pooled heatï¿¾inactivated supernatant from Day 42 non-leucoreduced human packed red
blood cell concentrates; SEM, standard error of the mean; SvO2, mixed venous
oxygen saturation; TRALI, transfusion-related acute lung injury. Averages Â±
SEM for each group are shown. Data and P-values were calculated using
mixed modelling.
Table 4 Supernatant composition
PRBC PLT
â€œfresh
PRBCâ€
â€œstored
PRBCâ€
â€œfresh
PLTâ€
â€œstored
PLTâ€
Hb (g/dL) 0.01 0.33 0.01 0.02
K+ (mmol/L) 2.0 44.4 3.9 4.4
Na+ (mmol/L) 143 105 157 158
Cl- (mmol/L) 112 103 74 77
Glucose (mmol/
L)
28.0 14.3 7.0 0.0
Lactate (mmol/
L)
6.5 29.6 4.6 18.0
sCD40L (ng/ml) 0.24 1.50 0.48 0.73
EGF (pg/ml) 0 298 5 69
ENA-78 (pg/ml) 63 1,555 226 6,333
GRO-a (pg/ml) 352 662 110.1 692
IL-8 (pg/ml) 28 10,004 323 379
IL-16 (pg/ml) 50 19,754 225 260
MCP-1 (pg/ml) 0 422 0 0
Cl-
, chlorine anion; EGF, epidermal growth factor; ENA-78, epithelial derived
neutrophil activating 78; â€œfresh PLTâ€, pooled heat-inactivated supernatant from
Day 1 non-leucoreduced human platelet concentrates; â€œfresh PRBCâ€, pooled
heat-inactivated supernatant from Day 1 non-leucoreduced human packed
red blood cell concentrates; GRO-a, growth related oncogene alpha; Hb,
haemoglobin; IL-8, interleukin 8; IL-16, interleukin 16; K+
, potassium cation;
MCP-1, monocyte chemotactic protein 1; Na+
, sodium anion; PLT; platelet
concentrates; PRBC; packed red blood cell concentrates; sCD40L, soluble CD40
ligand; â€œstored PLTâ€, pooled heat-inactivated supernatant from Day 5 nonï¿¾leucoreduced human platelet concentrates; â€œstored PRBCâ€, pooled heatï¿¾inactivated supernatant from Day 42 non-leucoreduced human packed red
blood cell concentrates. Both â€œstored PRBCâ€ and â€œstored PLTâ€ demonstrated
increased levels of lactate and sCD40L as well as decreased pH and glucose
levels compared to fresh equivalents. Additionally â€œstored PRBCâ€
demonstrated increased haemoglobin and potassium levels compared to
â€œfresh PRBCâ€ and to â€œstored PLTâ€. Higher concentrations of EGF, ENA-78 and
GRO-a, were present in both â€œstored PLTâ€ and â€œstored PRBCâ€ relative to fresh
equivalents. However the concentrations of IL-8, IL-16 and MCP-1 were only
increased only â€œstored PRBCâ€. Additionally, concentrations of EGF, IL-8, IL-16
and MCP-1 were all higher in â€œstored PRBCâ€ than in â€œstored PLTâ€. Conversely,
concentrations of ENA-78 and GRO-a were higher in â€œstored PLTâ€ than in
â€œstored PRBCâ€.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 9 of 14

this alternative approach. First, while the preparation of
ovine PRBC is not technically difficult, this process
requires standardisation and validation to ensure that
the ovine PRBC provide a suitable model of human
PRBC. Second, as has been demonstrated in small aniï¿¾mal models [45,47-49], there are likely to be differences
between the storage lesions of ovine and human PRBC.
Detailed comparative data comparing the storage lesions
of ovine PRBC and human PRBC are, therefore, essenï¿¾tial to validate an ovine model of homologous transfuï¿¾sion for the study of effects related to the age of blood.
While future studies are planned to address these limitaï¿¾tions of homologous transfusion models, it was felt that,
at the present time, the transfusion of heat-inactivated
supernatant from human blood products, provided a
more relevant clinical model of TRALI.
PRBC that have not undergone pre-storage leucoreï¿¾duction comprise a significant proportion of the PRBC
used in the USA (approximately 20% of the approxiï¿¾mately 17 million PRBC transfused in 2009) [50].
Hence, the findings of this study are of particular cliniï¿¾cal relevance to the USA and other countries in which
universal pre-storage leucoreduction of blood products
has not yet been implemented. Leucoreduction has
been shown to reduce the concentration of leucocyteï¿¾derived factors in the storage lesion of cellular blood
products [41]; however, whether it also reduces the
risk of TRALI remains a matter of conjecture based
upon current evidence [7,12,18,51]. Of note, analyses
of 89 TRALI cases from two tertiary care medical cenï¿¾tres in the USA [7] and of 60 TRALI cases in The
Netherlands [8] failed to demonstrate any association
between the length of storage of leucoreduced PRBC
and TRALI, although these analyses may have been
confounded by the presence of leucocyte antibodies in
a proportion of leucoreduced PRBC. Hence, the imporï¿¾tance of the present study, and the ovine model, as a
historical marker allowing for further investigation of
the effects of leucoreduction upon TRALI pathogenï¿¾esis. Accordingly, follow-up studies using equivalent
leucoreduced PRBC have been planned to identify
common BRM and to elucidate the effects that transï¿¾fusion of supernatant from stored leucoreduced human
PRBC may have upon TRALI pathogenesis in the
$!
!"$#$"

!"
"#!
!"
"#!



	





 "

%$#! "
Figure 3 Neutrophil priming ability. Ability to prime fMLP-induced human neutrophil respiratory burst function is shown as mean of n = 4
experiments. Error bars indicate SEM. Both â€œstored PRBCâ€ and â€œstored PLTâ€ display increased ability to prime fMLP-induced neutrophil respiratory
burst than the equivalent fresh product. There was no difference between the ability of â€œstored PRBCâ€ and â€œstored PLTâ€ to prime fMLP-induced
neutrophil respiratory burst. # P < 0.001 â€œstored PLTâ€ vs. â€œfresh PLTâ€ using a one-way ANOVA with Bonferroniâ€™s multiple comparisons adjustment.
* P < 0.001 â€œstored PRBCâ€ vs. â€œfresh PRBCâ€ using a one-way ANOVA with Bonferroniâ€™s multiple comparisons adjustment. ns P > 0.05 â€œstored PRBCâ€
vs. â€œstored PLTâ€ using a one-way ANOVA with Bonferroniâ€™s multiple comparisons adjustment. ANOVA, analysis of variance; fMLP, Nï¿¾formylmethionyl-leucyl-phenylalanine; â€œfresh PLTâ€, pooled heat-inactivated supernatant from Day 1 non-leucoreduced human platelet
concentrates; â€œfresh PRBCâ€, pooled heat-inactivated supernatant from Day 1 non-leucoreduced human packed red blood cell concentrates; min,
minute; O2
-
, superoxide anion; PAF, platelet activating factor; PLT, platelet concentrate, PRBC packed red blood cells; â€œstored PLTâ€, pooled heatï¿¾inactivated supernatant from Day 5 non-leucoreduced human platelet concentrates; â€œstored PRBCâ€, pooled heat-inactivated supernatant from day
42 non-leucoreduced human packed red blood cell concentrates; SEM, standard error of the mean.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 10 of 14

ovine model. These effects may then be compared to
those reported in the present study.
The definition of TRALI used in this study included
cases in which a sustained worsening of pre-existing
hypoxaemia was evident following transfusion. This was
justified because the control groups and detailed moniï¿¾toring used in the experimental setting make it possible
to clearly define such cases. Two separate analyses conï¿¾firmed the robustness of these data. First, analyses of
averaged data demonstrated that the LPS-stored group
had lower PaO2 values post-transfusion compared to the
LPS-control group (Figure 2). Second, analyses using
mixed modelling demonstrated that the LPS-stored
group had lower PaO2 values post-transfusion compared
to both the LPS-control and LPS-fresh groups (Table 2).
Thus, it was possible to conclude that the worsening
hypoxaemia was related to the transfusion of â€œstored
PRBCâ€ rather than the continued effects of LPS-infuï¿¾sion. In contrast to the experimental setting, defining
worsening hypoxaemia related to transfusion is probleï¿¾matic in the clinical setting. Therefore, more restrictive
criteria, in which TRALI is only defined by the onset of
new hypoxaemia, are used clinically [52,53]. However,
Koch et al. have demonstrated that, regardless of transï¿¾fusion history, over 60% of cardiac surgical patients
were hypoxaemic upon admission to ICU, this highlightï¿¾ing the difficulty in applying current TRALI definitions
in the critical care setting [54].
The relative similarity in pulmonary anatomy and phyï¿¾siology between sheep and humans [55-59] represents a
significant advantage of this ovine model over existing
small animal rodent models of TRALI. Another distinct
advantage is the larger size of the sheep relative to the
rats and mice used for other TRALI models. This
enabled detailed monitoring of the respiratory and haeï¿¾modynamic changes associated with TRALI. In sheep
that developed TRALI, the observed reduction in Cstat
and decrement in oxygenation represents a physiological
manifestation of the loss of the open alveolar structure
evident upon post-mortem histological analysis. The
continuous physiological monitoring also revealed that
TRALI was associated with development of pulmonary
arterial hypertension, further increasing the workload on
the right heart, which may lead to poorer tissue oxygeï¿¾nation, with increased venous pressures and reduced
cardiac output. Hence, TRALI worsens oxygenation at
the arterio-alveolar interphase, as well as diminishing
tissue oxygen delivery, due to the cardiovascular perturï¿¾bations. In addition to predisposing the development of
TRALI, it is possible that by worsening tissue dysoxia in
other organs the transfusion of stored blood might also
contribute to the development of multiple organ dysï¿¾function syndrome (MODS) [21,60], although further
studies would be required to investigate this hypothesis.
This study provides further evidence that both recipiï¿¾ent (first event) and blood product (second event) facï¿¾tors contribute to the development of TRALI. Such a
two-event mechanism was first postulated for some
instances of ARDS [61], then was adapted for TRALI
[15], and recently has been re-stated as a threshold
mechanism for TRALI [14]. This proposes that the
development of TRALI is associated with both the
severity of underlying illness and the strength of blood
product factors [14]. This interaction may provide an
explanation for both the unexpected lack of TRALI in a
single LPS-infused sheep transfused with â€œstored PRBCâ€
as well as the unexpected development of TRALI in a
single LPS-infused sheep transfused with â€œfresh PRBC.â€
In the former case, it is possible that recipient factors
were protective against TRALI. Genetic factors have
been implicated in the development of ALI [62], and it
is possible that they may also play a role in TRALI as
only some patients transfused with stored PRBC go on
to develop TRALI. In the latter case, post hoc analyses
revealed that abnormal baseline respiratory data were
indicative of pre-existing lung injury (initial PaO2/FiO2
was 277.5, which recovered to 452.5 at the start of the
experiment). Therefore, we speculate that pre-existing
injury in combination with LPS-infusion may have renï¿¾dered this sheep more susceptible to the development of
TRALI, such that a weaker second event stimulus
("fresh PRBCâ€) was sufficient to induce TRALI. This
would be consistent with the proposed threshold
mechanism. Thus, critical care patients may be particuï¿¾larly susceptible to the development of TRALI because
of the severity of their illness. In addition, the risk of
developing TRALI may be further increased if they are
transfused with stored blood products which have a
higher BRM content [1-3,5,6,11,12,28-31,43-45].
Finally, this study demonstrated that the injury profile
of TRALI induced by â€œstored PRBCâ€ was more severe
than that previously described by â€œstored PLTâ€ [10].
Data re-modelling confirmed a reduction in MAP and
CO as well as higher CVP and temperature in TRALI
induced by â€œstored PRBC.â€ The strength of the recipient
factors was consistent, as the same dose of LPS was
used in both studies [10]. Therefore, the difference in
symptoms may be attributable to a difference in blood
product factors. This is supported by the higher concenï¿¾trations of EGF, IL-8, IL-16, MCP-1, lactate and potasï¿¾sium measured in â€œstored PRBCâ€ than in â€œstored PLT.â€
The observation that these higher concentrations, preï¿¾sent in the transfused blood product were associated
with more severe symptoms is suggestive of a doseï¿¾response relationship; however, further research would
be required to confirm this hypothesis. Also, the
mechanism by which each of these potential BRM may
act requires further elucidation. As no differences were
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 11 of 14

observed in the in vitro neutrophil priming ability of
â€œstored PRBCâ€ and â€œstored PLT,â€ direct actions of these
potential BRMs upon neutrophils are unlikely to contriï¿¾bute to the differences observed in vivo. It is possible
that other cells, such as platelets [38], T-lymphocytes
[63] and endothelial cells [16], which also contribute to
the pathophysiology of TRALI, may have contributed to
the observed haemodynamic differences and this warï¿¾rants further investigation.
Conclusions
This study has confirmed that the transfusion of soluï¿¾ble factors present in stored blood products (that is,
PRBC) presents a significantly increased risk of TRALI
compared to equivalent fresh products. Symptoms
associated with TRALI induced by â€œstored PRBCâ€
were more severe than for TRALI induced by â€œstored
PLT,â€ possibly due to an increased range and concenï¿¾tration of cytokines and other factors present in the
â€œstored PRBC,â€ and is suggestive of a dose-response
relationship. Improved understanding of the injurious
soluble factors present in stored blood products is
required to direct the manufacture of safer blood
components. This study has also reaffirmed the
importance of recipient (patient) factors in the develï¿¾opment of TRALI as only LPS-primed sheep went on
to develop TRALI. Hence, severely ill patients, such as
those in critical care units, may be at increased risk of
developing TRALI. This study reaffirms the fact that
blood transfusion has associated risk and should be
prescribed with prudence, particularly in the critical
care setting.
Key messages
â€¢ In an in vivo ovine model, sick sheep (that is,
infused with LPS: 15 Î¼g/kg i.v.) transfused with
â€œstored PRBCâ€ predominantly developed TRALI (P =
0.01 vs. control groups).
â€¢ Development of TRALI induced by â€œstored PRBCâ€
was associated with haemodynamic changes that
were more severe than in TRALI induced by â€œstored
PLTâ€ in a previous study [10], and may be because
of differences in the storage lesions of â€œstored
PRBCâ€ and â€œstored PLT.â€
â€¢ The age of the blood product transfused (that is,
fresh vs. date-of-expiry), the type of blood product
transfused (that is, PRBC vs. WB-PLTs) and the
health of the recipient (that is, saline vs. LPS as a
first event), therefore, all contributed to determine
the severity of TRALI in the ovine model.
â€¢ Critical care patients may, therefore, be particularly
susceptible to development of TRALI because of the
severity of their illness and their increased reliance
upon transfusion of blood products, and this
susceptibility may be further increased with the
transfusion of stored blood products.
Abbreviations
ABG: arterial blood gas; ALI: acute lung injury; ARDS: acute respiratory
distress syndrome; BRM: biological response modifier; CO: cardiac output;
CPD: citrate phosphate dextrose; Cstat: static pulmonary compliance; CVP:
central venous pressure; d1-PLT-S/N: pooled heat-inactivated supernatant
from Day 1 non-leucoreduced human whole blood platelet concentrates;
d5-PLT-S/N: pooled heat-inactivated supernatant from Day 5 nonï¿¾leucoreduced human whole blood platelet concentrates; EGF: epidermal
growth factor; ENA-78: epithelial derived neutrophil activating 78; EtCO2: end
tidal carbon dioxide; ESLD: end-stage liver disease; FFP: fresh frozen plasma;
FiO2: fraction of inspired oxygen; fMLP: N-formylmethionyl-leucylï¿¾phenylalanine; â€œfresh PLT": pooled heat-inactivated supernatant from Day 1
non-leucoreduced human platelet concentrates; â€œfresh PRBC": pooled heatï¿¾inactivated supernatant from Day 1 non-leucoreduced human packed red
blood cell concentrates; GI: gastrointestinal; GRO-Î±: growth related
oncogene alpha; HETE: hydroxyl eicosotetranoic acid; IGFBP-1: insulin-like
growth factor-binding protein 1; IL-8: interleukin 8; IL-16: interleukin 16; LPS:
lipopolysaccharide; MAP: mean arterial pressure; MCP-1: monocyte
chemotactic protein 1; MIF: macrophage inhibitory factor; MODS: multiple
organ dysfunction syndrome; N/A: not applicable; O2
-
: superoxide anion;
O2sat: oxygen saturation; PaCO2: arterial partial pressure of carbon dioxide;
PAF: platelet activating factor; PaO2: arterial partial pressure of oxygen; PAP:
pulmonary artery pressure; PDGF-BB: platelet-derived growth factor BB; PLT:
platelet concentrate; PRBC: packed red blood cells; RLI: relative light
intensity; SAGM: saline-adenine-glucose-mannitol; sCD40L: soluble CD40
ligand; â€œstored PLT": pooled heat-inactivated supernatant from Day 5 nonï¿¾leucoreduced human platelet concentrates; â€œstored PRBC": pooled heatï¿¾inactivated supernatant from Day 42 non-leucoreduced human packed red
blood cell concentrates; SvO2: mixed venous oxygen saturation; TRALI:
transfusion-related acute lung injury.
Acknowledgements
The authors thank the administrative, animal handling and veterinary staff at
MERF for their kind assistance, and Kimble Dunster for his help in setting up
data collection protocols. The authors also thank the Australian Red Cross
Blood Service staff for their assistance in collecting and processing the PRBC,
in particular Margaret Hester, Viktor Klajic and John Walton. The authors
acknowledge Australian governments that fully fund the Australian Red
Cross Blood Service for the provision of blood products and services to the
Australian community. This study was co-funded by the Prince Charles
Hospital Research Foundation, the Critical Care Research Group and the
University of Queensland.
Author details
1
Research and Development, Australian Red Cross Blood Service, 44 Musk
Avenue, Kelvin Grove, Brisbane, QLD 4059, Australia. 2
The School of
Medicine, The University of Queensland, 288 Herston Road, Herston,
Brisbane, QLD, Australia. 3
The Critical Care Research Group, The Prince
Charles Hospital, Rode Road, Chermside, Brisbane, QLD 4059, Australia. 4
The
Prince Charles Hospital, Rode Road, Chermside, Brisbane, QLD 4032, Australia.
5
Institute of Health and Biomedical Innovation and School of Public Health,
Queensland University of Technology, 60 Musk Avenue, Kelvin Grove,
Brisbane, QLD 4059, Australia. 6
Research and Development, Australian Red
Cross Blood Service, Corner Balston and Kavanagh Streets, Southbank,
Melbourne, VIC 3006, Australia. 7
Haematology Department, The Princess
Alexandra Hospital, 199 Ipswich Road, Wooloongabba, Brisbane, QLD 4102,
Australia. 8
Research Department, Bonfils Blood Center, 717 Yosemite Street,
Denver, CO 80230, USA. 9
The Department of Pediatrics, School of Medicine,
University of Colorado Denver, 12700 East 19th Avenue, Aurora, CO 80045,
USA. 10The Department of Surgery, School of Medicine, University of
Colorado Denver, 12700 East 19th Avenue, Aurora, CO 80045, USA. 11Cardiac
Surgery Research Unit, The Prince Charles Hospital, Rode Road, Chermside,
Brisbane, QLD 4059, Australia.
Authorsâ€™ contributions
JPT, JFF, KIC, AGB, PW, CSS and YLF contributed to obtaining funding for this
study and the conception and design of the study. JPT, KIC and YLF coï¿¾Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 12 of 14

ordinated the provision of PRBC, and contributed to the supernatant
preparation and pooling. JPT, JFF, KIC and YLF contributed to the animal
experiments. JPT, MN, KMG, AYZ and YLF contributed to the laboratory
testing. All authors contributed to the analysis and interpretation of data as
well as to the preparation of this manuscript.
Competing interests
JPT, KIC, KMG, AYZ and YLF were employees of the Australian Red Cross
Blood Service during the completion of this study. The authors declare that
they have no other competing interests.
Received: 29 August 2011 Revised: 11 January 2012
Accepted: 1 February 2012 Published: 1 February 2012
References
1. Lelubre C, Piagnerelli M, Vincent J-L: Association between duration of
storage of transfused red blood cells and morbidity and mortality in
adult patients: myth or reality? Transfusion 2009, 49:1384-1394.
2. Zimrin AB, Hess JR: Current issues relating to the transfusion of stored
red blood cells. Vox Sang 2009, 96:93-103.
3. Spinella PC, Carroll CL, Staff I, Gross R, Mc Quay J, Keibel L, Wade CE,
Holcomb JB: Duration of red blood cell storage is associated with
increased incidence of deep vein thrombosis and in hospital mortality
in patients with traumatic injuries. Crit Care 2009, 13:R151.
4. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T,
Blackstone EH: Duration of red-cell storage and complications after
cardiac surgery. N Engl J Med 2008, 358:1229-1239.
5. Karam O, Tucci M, Bateman ST, Ducruet T, Spinella PC, Randolph AG,
Lacroix J: Association between length of storage of red blood cell units
and outcome of critically ill children: a prospective observational study.
Crit Care 2010, 14:R57.
6. Pettila V, Westbrook AJ, Nichol AD, Bailey MJ, Wood EM, Syres G, Phillips LE,
Street A, French C, Murray L, Orford N, Santamaria JD, Bellomo R,
Cooper DJ, for the Blood Observational Study Investigators for the ANZICS
Clinical Trials Group: Age of red blood cells and mortality in the critically
ill. Crit Care 2011, 15:R116.
7. Toy P, Gajic O, Bacchetti P, Looney MR, Gropper MA, Hubmayr R, Lowell CA,
Norris PJ, Murphy EL, Weiskopf RB, Wilson G, Koenigsberg M, Lee D,
Schuller R, Wu P, Grimes B, Gandhi MJ, Winters JL, Mair D, Hirschler N,
Sanchez Rosen R, Matthay MA: Transfusion related acute lung injury:
incidence and risk factors. Blood 2011.
8. Middelburg RA, Borkent B, Jansen M, van de Watering LMG, Wiersumï¿¾Osselton JC, Schipperus MR, Beckers EAM, BriÃ«t E, van der Bom JG: Storage
time of blood products and transfusion-related acute lung injury.
Transfusion 2011.
9. Silliman CC, Bjornsen AJ, Wyman TH, Kelher M, Allard J, Bieber S, Voelkel NF:
Plasma and lipids from stored platelets cause acute lung injury in an
animal model. Transfusion 2003, 43:633-640.
10. Tung JP, Fung YL, Nataatmadja M, Colebourne KI, Esmaeel HM, Wilson K,
Barnett AG, Wood P, Silliman CC, Fraser JF: A novel in vivo ovine model of
transfusion-related acute lung injury (TRALI). Vox Sang 2011, 100:219-230.
11. Silliman CC, Paterson AJ, Dickey WO, Stroneck DF, Popovsky MA,
Caldwell SA, Ambruso DR: The association of biologically active lipids
with the development of transfusion-related acute lung injury: a
retrospective study. Transfusion 1997, 37:719-726.
12. Kelher MR, Masuno T, Moore EE, Damle S, Meng X, Song Y, Liang X,
Niedzinski J, Geier SS, Khan SY, Gamboni-Robertson F, Silliman CC: Plasma
from stored packed red blood cells and MHC class I antibodies causes
acute lung injury in a 2-event in vivo rat model. Blood 2009,
113:2079-2087.
13. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA:
Proceedings of a consensus conference: towards an understanding of
TRALI. Transfus Med Rev 2005, 19:2-31.
14. Bux J, Sachs UJ: The pathogenesis of transfusion-related acute lung
injury (TRALI). Br J Haematol 2007, 136:788-799.
15. Silliman CC: The two-event model of transfusion-related acute lung
injury. Crit Care Med 2006, 34:S124-131.
16. Silliman CC, Fung YL, Bradley Ball J, Khan SY: Transfusion-related acute
lung injury (TRALI): current concepts and misconceptions. Blood Rev
2009, 23:245-255.
17. FDA: Center for Biologics Research and Evaluation (CBER): Fatalities
reported to FDA following blood collection and transfusion- Annual
summary for fiscal year 2009.[http://www.fda.gov/downloads/
BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/
TransfusionDonationFatalities/UCM205620.pdf].
18. Chapman CE, Stainsby D, Jones H, Love E, Massey E, Win N, Navarrete C,
Lucas G, Soni N, Morgan C, Choo L, Cohen H, Williamson LM: Ten years of
hemovigilance reports of transfusion-related acute lung injury in the
United Kingdom and the impact of preferential use of male donor
plasma. Transfusion 2009, 49:440-452.
19. Keller-Stanislawski B, Lohmann A, GÃ¼nay S, Heiden M, Funk MB: The
German Haemovigilance System-reports of serious adverse transfusion
reactions between 1997 and 2007. Transfus Med 2009, 19:340-349.
20. Wallis JP: Transfusion-related acute lung injury (TRALI)â€“under-diagnosed
and under-reported. Br J Anaesth 2003, 90:573-576.
21. Vamvakas EC, Blajchman MA: Blood still kills: six strategies to further
reduce allogeneic blood transfusion-related mortality. Transfus Med Rev
2010, 24:77-124.
22. Benson AB, Moss M, Silliman CC: Transfusion-related acute lung injury
(TRALI): a clinical review with emphasis on the critically ill. Br J Haematol
2009, 147:431-443.
23. Gajic O, Rana R, Winters JL, Yilmaz M, Mendez JL, Rickman OB, Oâ€™Byrne MM,
Evenson LK, Malinchoc M, DeGoey SR, Afessa B, Hubmayr RD, Moore SB:
Transfusion-related acute lung injury in the critically ill: prospective
nested case-control study. Am J Respir Crit Care Med 2007, 176:886-891.
24. Vlaar APJ, Binnekade JM, Prins D, van Stein D, Hofstra JJ, Schultz MJ,
Juffermans NP: Risk factors and outcome of transfusion-related acute
lung injury in the critically ill: A nested case-control study. Crit Care Med
2010, 38:771-778.
25. Benson A, Austin G, Silliman C, Moss M: Transfusion Associated Acute
Respiratory Distress Syndrome (ARDS) in patients with gastrointestinal
bleeding: effect of end stage liver disease and the use of fresh frozen
plasma. Am J Respir Crit Care Med 2009, 179:A4639.
26. Reil A, Keller-Stanislawski B, Gunay S, Bux J: Specificities of leucocyte
alloantibodies in transfusion-related acute lung injury and results of
leucocyte antibody screening of blood donors. Vox Sang 2008,
95:313-317.
27. Engelfriet CP, Reesink HW, Wendel S, Biagini S, Trigo F, Fontao-Wendel R,
Taaning E, Jorgensen J, Riisom K, Krusius T, Koskinen S, Kretschmer V,
Karger R, Lawlor E, Okazaki H, Charlewood R, Brand A, Solheim BG,
Flesland O, Letowska M, Zupanska B, Muniz-Diaz E, Nogues N, Senn M,
Mansouri-Taleghani B, Chapman CE, Massey E, Navarette C, Win N,
Williamson LM, et al: Measures to prevent TRALI. Vox Sang 2007,
92:258-277.
28. Silliman CC, Moore EE, Kelher MR, Khan SY, Gellar L, Elzi DJ: Identification
of lipids that accumulate during the routine storage of prestorage
leukoreduced red blood cells and cause acute lung injury. Transfusion
2011, 51:2549-2554.
29. Khan SY, Kelher MR, Heal JM, Blumberg N, Boshkov LK, Phipps R,
Gettings KF, McLaughlin NJ, Silliman CC: Soluble CD40 ligand accumulates
in stored blood components, primes neutrophils through CD40, and is a
potential cofactor in the development of transfusion-related acute lung
injury. Blood 2006, 108:2455-2462.
30. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR: Partial
characterization of lipids that develop during the routine storage of
blood and prime the neutrophil NADPH oxidase. J Lab Clin Med 1994,
124:684-694.
31. Silliman CC, Dickey WO, Paterson AJ, Thurman GW, Clay KL, Johnson CA,
Ambruso DR: Analysis of the priming activity of lipids generated during
routine storage of platelet concentrates. Transfusion 1996, 36:133-139.
32. Fung YL, Fraser JF, Wood P, Minchinton RM, Silliman CC: The systemic
inflammatory response syndrome induces functional changes and
relative hyporesponsiveness in neutrophils. J Crit Care 2008, 23:542-549.
33. The R Project for Statistical Computing: a Language and Environment
for Statistical Computing. 2011 [http://www.R-project.org].
34. Dobson A, Barnett AG: Clustered and Longitudinal Data. An Introduction to
Generalized Linear Models. 3 edition. Champan and Hall/CRC; 2008, CRC
Texts in Statistical Science Series.
35. Cognasse F, Boussoulade F, Chavarin P, Acquart S, Fabrigli P, Lamy B,
Garraud O: Release of potential immunomodulatory factors during
platelet storage. Transfusion 2006, 46:1184-1189.
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 13 of 14

36. Fung L: The recipient side of TRALI-the role of patient neutrophils. ISBT
Sci Ser 2007, 2:135-140.
37. Silliman CC, Thurman GW, Ambruso DR: Stored blood components
contain agents that prime the neutrophil NADPH oxidase through the
platelet-activating-factor receptor. Vox Sang 1992, 63:133-136.
38. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA:
Platelet depletion and aspirin treatment protect mice in a two-event
model of transfusion-related acute lung injury. J Clin Invest 2009,
119:3450-3461.
39. Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL,
Ambruso DR: Plasma and lipids from stored packed red blood cells
cause acute lung injury in an animal model. J Clin Invest 1998,
101:1458-1467.
40. Silliman CC, Khan SY, Ball JB, Kelher MR, Marschner S: Mirasol Pathogen
Reduction Technology treatment does not affect acute lung injury in a
two-event in vivo model caused by stored blood components. Vox Sang
2010, 98:525-530.
41. Shanwell A, Kristiansson M, Remberger M, RingdÃ©n O: Generation of
cytokines in red cell concentrates during storage is prevented by
prestorage white cell reduction. Transfusion 1997, 37:678-684.
42. Glenister KM, Sparrow RL: Level of platelet-derived cytokines in
leukoreduced red blood cells is influenced by the processing method
and type of leukoreduction filter. Transfusion 2010, 50:185-189.
43. Tuinman P, Vlaar A, Cornet A, Hofstra J, Levi M, Meijers J, Beishuizen A,
Schultz M, Groeneveld AJ, Juffermans N: Blood transfusion during cardiac
surgery is associated with inflammation and coagulation in the lung: a
case control study. Crit Care 2011, 15:R59.
44. Vlaar AP, Hofstra JJ, Levi M, Kulik W, Nieuwland R, Tool AT, Schultz MJ, de
Korte D, Juffermans NP: Supernatant of aged erythrocytes causes lung
inflammation and coagulopathy in a â€œtwo-hitâ€ in vivo syngeneic
transfusion model. Anesthesiology 2010, 113:92-103.
45. Vlaar APJ, Hofstra JJ, Kulik W, van Lenthe H, Nieuwland R, Schultz MJ,
Levi MM, Roelofs JJTH, Tool ATJ, de Korte D, Juffermans NP: Supernatant of
stored platelets causes lung inflammation and coagulopathy in a novel
in vivo transfusion model. Blood 2010, 116:1360-1368.
46. Mangalmurti NS, Xiong Z, Hulver M, Ranganathan M, Liu XH, Oriss T,
Fitzpatrick M, Rubin M, Triulzi D, Choi A, Lee JS: Loss of red cell chemokine
scavenging promotes transfusion-related lung inflammation. Blood 2009,
113:1158-1166.
47. Dâ€™Almeida MS, Jagger J, Duggan M, White M, Ellis C, Chin-Yee IH: A
comparison of biochemical and functional alterations of rat and human
erythrocytes stored in CPDA-1 for 29 days: implications for animal
models of transfusion. Transfus Med 2000, 10:291-303.
48. Makley AT, Goodman MD, Friend LA, Johannigman JA, Dorlac WC,
Lentsch AB, Pritts TA: Murine blood banking: characterization and
comparisons to human blood. Shock 2010, 34:40-45.
49. Dâ€™Almeida Mark S, Gray D, Martin C, Ellis Christopher G, Chin-Yee Ian H:
Effect of prophylactic transfusion of stored RBCs on oxygen reserve in
response to acute isovolemic hemorrhage in a rodent model. Transfusion
2001, 41:950-956.
50. US Department of Health and Human Services: The 2009 national blood
collection and utilization survey report. Washington, DC: US Department
of Health and Human Services, Office of the Assistant Secretary of Health;
2011.
51. Blumberg N, Heal JM, Gettings KF, Phipps RP, Masel D, Refaai MA,
Kirkley SA, Fialkow LB: An association between decreased
cardiopulmonary complications (transfusion-related acute lung injury
and transfusion-associated circulatory overload) and implementation of
universal leukoreduction of blood transfusions. Transfusion 2010,
50:2738-2744.
52. Toy P, Hollis-Perry KM, Jun J, Nakagawa M: Recipients of blood from a
donor with multiple HLA antibodies: a lookback study of transfusionï¿¾related acute lung injury. Transfusion 2004, 44:1683-1688.
53. Kleinman S, Caulfield T, Chan P, Davenport R, McFarland J, McPhedran S,
Meade M, Morrison D, Pinsent T, Robillard P, Slinger P: Toward an
understanding of transfusion-related acute lung injury: statement of a
consensus panel. Transfusion 2004, 44:1774-1789.
54. Koch C, Li L, Figueroa P, Mihaljevic T, Svensson L, Blackstone EH:
Transfusion and Pulmonary Morbidity After Cardiac Surgery. Ann Thorac
Surg 2009, 88:1410-1418.
55. Harris A: Towards an ovine model of cystic fibrosis. Hum Mol Genet 1997,
6:2191-2194.
56. Cotton CU, Lawson EE, Boucher RC, Gatzy JT: Bioelectric properties and
ion transport of airways excised from adult and fetal sheep. J Appl
Physiol 1983, 55:1542-1549.
57. Olver RE, Robinson EJ: Sodium and chloride transport by the tracheal
epithelium of fetal, new-born and adult sheep. J Physiol 1986,
375:377-390.
58. Wallace MJ, Hooper SB, Harding R: Effects of elevated fetal cortisol
concentrations on the volume, secretion, and reabsorption of lung
liquid. Am J Physiol 1995, 269:R881-887.
59. Wallace MJ, Hooper SB, Harding R: Role of the adrenal glands in the
maturation of lung liquid secretory mechanisms in fetal sheep. Am J
Physiol 1996, 270:R33-40.
60. Looney MR, Gropper MA, Matthay MA: Transfusion-related acute lung
injury: a review. Chest 2004, 126:249-258.
61. Salzer WL, McCall CE: Primed stimulation of isolated perfused rabbit lung
by endotoxin and platelet activating factor induces enhanced
production of thromboxane and lung injury. J Clin Invest 1990,
85:1135-1143.
62. Flores C, Pino-Yanes MdM, Villar J: A quality assessment of genetic
association studies supporting susceptibility and outcome in acute lung
injury. Crit Care 2008, 12:R130.
63. Fung YL, Kim M, Tabuchi A, Aslam R, Speck ER, Chow L, Kuebler WM,
Freedman J, Semple JW: Recipient T lymphocytes modulate the severity
of antibody-mediated transfusion-related acute lung injury. Blood 2010,
116:3073-3079.
doi:10.1186/cc11178
Cite this article as: Tung et al.: Age of blood and recipient factors
determine the severity of transfusion-related acute lung injury (TRALI).
Critical Care 2012 16:R19.
Submit your next manuscript to BioMed Central
and take full advantage of: 
â€¢ Convenient online submission
â€¢ Thorough peer review
â€¢ No space constraints or color figure charges
â€¢ Immediate publication on acceptance
â€¢ Inclusion in PubMed, CAS, Scopus and Google Scholar
â€¢ Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tung et al. Critical Care 2012, 16:R19
http://ccforum.com/content/16/1/R19
Page 14 of 14

